Christopher R. Fenimore - 03 Feb 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
SVP Controller
Signature
/s/**Christopher R. Fenimore
Issuer symbol
REGN
Transactions as of
03 Feb 2023
Net transactions value
-$1,192,167
Form type
4
Filing time
07 Feb 2023, 15:10:43 UTC
Previous filing
20 Dec 2022
Next filing
27 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $1,352,150 +5,000 +27% $270.43 23,581 03 Feb 2023 Direct
transaction REGN Common Stock Tax liability $2,544,317 -3,286 -14% $774.29 20,295 03 Feb 2023 Direct
holding REGN Common Stock 1,779 03 Feb 2023 2021 GRAT
holding REGN Common Stock 5,000 03 Feb 2023 2022 GRAT
holding REGN Common Stock 1,480 03 Feb 2023 By 401(k) Plan
holding REGN Common Stock 1,897 03 Feb 2023 By Trust F1
holding REGN Common Stock 461 03 Feb 2023 by Trust for Daugh
holding REGN Common Stock 460 03 Feb 2023 by Trust for Son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -5,000 -100% $0.000000* 0 03 Feb 2023 Common Stock 5,000 $270.43 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.